Boston Scientific (NYSE:BSX) Price Target Cut to $75.00 by Analysts at Robert W. Baird

Key Points

• Robert W. Baird cut Boston Scientific’s price target to $75 from $78, while keeping an outperform rating. The new target still implies about 34% upside from the current share price.
• Other analysts have also trimmed targets recently, including Barclays, JPMorgan, RBC, Jefferies, and UBS, though the broader consensus remains Moderate Buy with an average price target of $92.71.
• Boston Scientific reported better-than-expected quarterly earnings and revenue, raised guidance, and approved a $5 billion share buyback authorization, signaling continued confidence in the business.

Boston Scientific (NYSE:BSX - Get Free Report) had its price objective dropped by Robert W. Baird from $78.00 to $75.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has an "outperform" rating on the medical equipment provider's stock. Robert W. Baird's price objective indicates a potential upside of 34.26% from the stock's current price.

A number of other brokerages also recently commented on BSX. Barclays cut their price objective on shares of Boston Scientific from $124.00 to $96.00 and set an "overweight" rating for the company in a research report on Thursday, April 23rd. JPMorgan Chase & Co. dropped their price target on shares of Boston Scientific from $135.00 to $100.00 and set an "overweight" rating on the stock in a research note on Thursday, February 5th. Royal Bank Of Canada cut their price target on shares of Boston Scientific from $105.00 to $100.00 and set an "outperform" rating for the company in a report on Thursday, April 23rd. Jefferies Financial Group reduced their price objective on shares of Boston Scientific from $110.00 to $100.00 and set a "buy" rating for the company in a research report on Wednesday, April 22nd. Finally, UBS Group lowered their price objective on Boston Scientific from $120.00 to $105.00 and set a "buy" rating on the stock in a report on Tuesday, March 17th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $92.71.

Boston Scientific Stock Up 6.0%

Boston Scientific stock opened at $55.86 on Tuesday. The stock has a 50 day moving average of $63.06 and a two-hundred day moving average of $81.33. Boston Scientific has a twelve month low of $52.52 and a twelve month high of $109.50. The stock has a market capitalization of $83.02 billion, a price-to-earnings ratio of 23.37, a PEG ratio of 0.97 and a beta of 0.62. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The business had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. During the same quarter in the previous year, the company posted $0.75 earnings per share. The company's revenue for the quarter was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, research analysts expect that Boston Scientific will post 3.38 earnings per share for the current year.

Boston Scientific declared that its Board of Directors has initiated a share buyback plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company's leadership believes its stock is undervalued.

Institutional Trading of Boston Scientific

A number of institutional investors have recently added to or reduced their stakes in the stock. Norges Bank purchased a new stake in shares of Boston Scientific during the 4th quarter worth approximately $2,199,395,000. Assenagon Asset Management S.A. increased its stake in Boston Scientific by 133.6% in the 1st quarter. Assenagon Asset Management S.A. now owns 10,057,936 shares of the medical equipment provider's stock valued at $631,135,000 after purchasing an additional 5,751,760 shares in the last quarter. Janus Henderson Group PLC increased its stake in Boston Scientific by 31.0% in the 1st quarter. Janus Henderson Group PLC now owns 16,497,366 shares of the medical equipment provider's stock valued at $1,035,202,000 after purchasing an additional 3,907,981 shares in the last quarter. Egerton Capital UK LLP raised its holdings in Boston Scientific by 223.7% during the third quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider's stock worth $518,660,000 after purchasing an additional 3,671,548 shares during the last quarter. Finally, Maverick Capital Ltd. purchased a new stake in Boston Scientific during the fourth quarter worth $280,735,000. Hedge funds and other institutional investors own 89.07% of the company's stock.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific announced a $2 billion accelerated share repurchase as part of its larger $5 billion buyback authorization, a move that can reduce share count and lift earnings per share over time. Boston Scientific enters into $2 billion accelerated share repurchase agreement
• Positive Sentiment: The company also invested $1.5 billion for about a 34% stake in MiRus, gaining an exclusive option to acquire MiRus’ TAVR business later if milestones are met. That gives Boston Scientific a potential pathway into the fast-growing structural heart market. Boston Scientific announces strategic investment in MiRus LLC
• Positive Sentiment: Late-breaking trial data for the SEISMIQ™ 4CE coronary intravascular lithotripsy catheter met primary safety and effectiveness endpoints in the FRACTURE IDE study, which could support future adoption and commercialization in calcified coronary artery disease. FRACTURE IDE trial of the Boston Scientific SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
• Neutral Sentiment: Wall Street analyst coverage remained favorable overall, with Needham and BTIG reiterating buy ratings, though Bank of America lowered its price target to $68 from $105. The mixed target action may temper some enthusiasm but still reflects bullish views on the stock. Boston Scientific Price Target Lowered to 68.00 at Bank of America

About Boston Scientific

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.